# FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Source: https://onco.cc/trials/nct06303505/  
OnCo record `nct06303505` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TUB-040 in ovarian cancer and non-small-cell lung cancer, run by Tubulis GmbH, now recruiting.

## Summary

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC is a phase 1/2 interventional study registered as NCT06303505 by Tubulis GmbH, with 250 participants planned, started 2024-06-12 and due to reach its primary completion in 2027-12. Interventions recorded: TUB-040.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06303505
- Phase: 1/2
- Setting: A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Tubulis GmbH
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT06303505: https://clinicaltrials.gov/study/NCT06303505

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Tubulis (Gilead)](https://onco.cc/companies/tubulis/)

---
JSON: https://onco.cc/api/v1/entities/nct06303505.json